Ligand Pharmaceuticals (LGND) Notes Payables (2012 - 2015)

Ligand Pharmaceuticals has disclosed Notes Payables across 4 years of filings, most recently posting $198.6 million for Q1 2015.

• Notes Payables for Q1 2015 came in at $198.6 million, up 3341.97% year-over-year; the trailing twelve-month figure through Mar 2015 was $198.6 million (up 3341.97% YoY), and the FY2014 annual result was $334000.0, down 96.33% from the prior year.
• Notes Payables came in at $198.6 million for Q1 2015 at Ligand Pharmaceuticals, up from $334000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $198.6 million in Q1 2015 to a low of $334000.0 in Q4 2014.
• The 4-year median for Notes Payables is $9.7 million (2012), against an average of $23.5 million.
• Across the five-year window, Notes Payables plunged 97.28% in 2014 and soared 3341.97% in 2015, its largest moves.
• Ligand Pharmaceuticals' Notes Payables stood at $14.8 million in 2012, then plunged by 38.6% to $9.1 million in 2013, then slumped by 96.33% to $334000.0 in 2014, then surged by 59351.2% to $198.6 million in 2015.
• The last three Notes Payables figures came in at $198.6 million (Q1 2015), $334000.0 (Q4 2014), and $337000.0 (Q3 2014), per Business Quant data.